Last reviewed · How we verify
NTQ5082 capsule
NTQ5082 capsule is a Small molecule drug developed by Nanjing Chia-tai Tianqing Pharmaceutical. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | NTQ5082 capsule |
|---|---|
| Sponsor | Nanjing Chia-tai Tianqing Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients (PHASE2)
- A Long-term Efficacy and Safety of NTQ5082 Capsules (PHASE3)
- A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients (PHASE3)
- Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy (PHASE2)
- Effect of Food of NTQ5082 in Healthy Subjects (PHASE1)
- A Phase 1 Clinical Trial of NTQ5082 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NTQ5082 capsule CI brief — competitive landscape report
- NTQ5082 capsule updates RSS · CI watch RSS
- Nanjing Chia-tai Tianqing Pharmaceutical portfolio CI
Frequently asked questions about NTQ5082 capsule
What is NTQ5082 capsule?
Who makes NTQ5082 capsule?
What development phase is NTQ5082 capsule in?
Related
- Manufacturer: Nanjing Chia-tai Tianqing Pharmaceutical — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing